All GLP-1 medications from licensed 503A compounding pharmacies Browse Products
Telehealth Provider — FDA safety data from public records
Bootstrapped GLP-1 telehealth platform focused on lower-cost compounded weight loss medication access, typically using asynchronous intake and a lean support model.
Website: medvi.com
Data last verified: 2026-04-25
Entity Type
Telehealth Provider
FDA Registration
Not shown
Warning Letters
1
Recalls
0
States Licensed
42
Compounding Status
unknown
MEDVi is best understood as a telehealth front end rather than a manufacturer. Patients usually encounter the brand through online intake, clinician review, subscription billing, fulfillment coordination, and follow-up support, while the medication supply chain sits behind the scenes with partner pharmacies or outsourcing facilities.
MEDVi reports coverage across 42 states, which suggests a relatively broad operating footprint rather than a niche single-state presence. For SEO and user trust, that means the important question is not just "is MEDVi legitimate" but "who is prescribing, who is compounding or dispensing, and what claims is the company making about those medications?"
Telehealth companies can scale quickly because marketing, acquisition, and patient communications are centralized. The tradeoff is that a polished consumer brand can sometimes hide weak transparency around pharmacy sourcing, state licensure details, refill logic, escalation paths, and how the company handles adverse events or billing disputes.
MEDVi sits in the budget end of the GLP-1 telehealth market. In FormBlends' broader market research, the company appears as a fast-scaling provider built around affordability, speed, and aggressive customer acquisition rather than premium clinical positioning.
The company is best understood as a telehealth distribution layer rather than a pharmacy. Patients interact with MEDVi through digital intake, subscription-style billing, and remote prescribing workflows, while the underlying medication supply is sourced through outside pharmacy partners.
MEDVi's model depends heavily on external compounding and fulfillment relationships rather than a public-facing FDA-registered facility owned by the brand itself. That makes pharmacy disclosure and product-source clarity especially important for prospective patients.
The main consumer questions around MEDVi are not just price, but how clearly the company describes compounded medication status, how easy support escalation is when something goes wrong, and whether rapid growth has outpaced compliance and service operations.
MEDVi is positioned as a lower-cost, high-volume telehealth option rather than a high-touch obesity medicine program.
The company relies on partner pharmacies rather than presenting itself here as a directly FDA-registered drug establishment.
Its FDA warning-letter history makes marketing language and compounded-drug disclosures especially important for patients to review.
1 FDA warning letter appear in this profile.
No recall events are currently shown in the FDA enforcement data surfaced here.
No direct FDA establishment registration record is displayed on this page.
The page shows an operating footprint of 42 states.
MEDVi does not appear in this profile as a directly FDA-registered drug establishment. That is common for telehealth platforms because they usually operate as prescriber and logistics layers while medications are sourced through partner pharmacies or outsourcing facilities.
MEDVi has 1 warning letter on record. The most recent entry in this profile is dated 2026-03-01 and focuses on misleading marketing claims for compounded glp-1 products. Warning letters matter because they show the FDA believed formal corrective action was needed, even though they are not the same thing as a final enforcement judgment.
No recall events are shown for MEDVi here. For consumers, that lowers one category of concern, but it still does not replace verification of sourcing, labeling, temperature handling, and pharmacy quality controls.
This profile does not currently show a meaningful adverse-event dataset for MEDVi. In practice, that usually means readers should lean more heavily on registration, recalls, warning letters, and pharmacy-partner transparency when evaluating risk.
No direct FDA establishment registration record is shown in this profile for MEDVi. For telehealth companies, that is often expected because the brand may coordinate care while external pharmacies or outsourcing facilities handle compounding or dispensing. Readers should verify the underlying pharmacy partner rather than relying on the consumer brand alone.
Misleading Marketing Claims for Compounded GLP-1 Products
FDA cited MEDVi for social and web marketing that implied compounded semaglutide products were equivalent to or carried the standing of FDA-approved GLP-1 drugs. The issue is especially important because patients can easily confuse telehealth marketing language with formal regulatory approval.
View on FDA.govNo recalls are currently displayed for MEDVi in the openFDA enforcement data surfaced on this page. That lowers one obvious risk signal, but it should not be treated as proof that all products, batches, or fulfillment practices are problem-free.
Source: openFDA Drug Enforcement API
This profile does not currently show a meaningful adverse-event summary for MEDVi. When that dataset is absent, readers should lean more on the documented public record around registration, recalls, warning letters, and pharmacy-partner transparency.
Source: FDA Adverse Event Reporting System (FAERS). Adverse event reports do not establish causation.
Which pharmacy or outsourcing facility is actually filling MEDVi prescriptions, and can you name it before checkout?
What does MEDVi tell patients about compounded versus FDA-approved products, and does that language avoid implying equivalence or approval where it does not exist?
How does MEDVi handle dose escalations, refill delays, refunds, cancellations, and temperature-sensitive shipping problems?
If a patient has a side effect or receives a product-quality concern, what is the human escalation path and how quickly does MEDVi respond?
Can MEDVi provide lot-level documentation, pharmacy details, and a clear explanation of what safety checks happen before medication is dispensed?
These related profiles are useful for searchers comparing MEDVi against adjacent providers or pharmacies. Reading similar pages side by side usually reveals whether a concern is unique to one company or common across this category.
This profile organizes public-source safety signals for MEDVi, including FDA registration status, warning letters, recalls, and any adverse event summary data available in the dataset.
A company can appear relatively clean here and still deserve more diligence, because absence of a warning letter or recall is not the same as proof of quality.
For telehealth provider pages especially, readers should distinguish between the consumer-facing brand and the pharmacy or facility that actually handles medication production or dispensing.
Use these links to validate the key claims in this profile and to separate the consumer-facing brand story from the underlying regulatory record.
MEDVi official website
Primary company website used to verify the direct-to-consumer telehealth offer described in this profile.
FDA warning letter index
Verification path for the warning-letter context and compounded-marketing scrutiny referenced on this page.
FormBlends partners with licensed 503A compounding pharmacies. Every compound is third-party tested with certificates of analysis.
Learn MoreDisclaimer: This page aggregates publicly available data from the FDA, state pharmacy boards, and other government sources. It is provided for informational purposes only and does not constitute medical or legal advice. FDA registration does not imply FDA approval or endorsement. The absence of warning letters or recalls does not guarantee safety or quality. Always consult your healthcare provider before making decisions about medications. Data may not reflect the most current status. Last updated: 2026-04-25.
503A vs 503B pharmacies
Understanding the FDA oversight difference.
How to read a Certificate of Analysis
What every CoA should include and red flags to watch for.
What FDA registration actually means
Registration vs approval: the distinction most people miss.
Choosing a compounding pharmacy
What to verify before you fill your first prescription.
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.
We do not currently have FDA registration data for MEDVi. This may mean the company operates under a different entity name or is regulated at the state level.
Yes, MEDVi has received 1 FDA warning letter. The most recent was issued on 2026-03-01. Warning letters indicate that the FDA found violations during review, but they are not final enforcement actions.
We have not found any recalls associated with MEDVi in the openFDA enforcement database.
MEDVi is categorized in this profile as a telehealth provider. That distinction matters because a telehealth brand, a 503A pharmacy, and a 503B outsourcing facility operate under different regulatory expectations.
No. A clean profile means we are not currently surfacing certain FDA signals like warning letters or recalls for MEDVi. It does not guarantee product quality, customer-service quality, or future regulatory compliance.
Patients should verify who is prescribing, which pharmacy or outsourcing facility is actually fulfilling the medication, what the company says about compounded versus FDA-approved products, and how billing, cancellations, and side-effect escalation are handled.